Success Metrics

Clinical Success Rate
79.6%

Based on 43 completed trials

Completion Rate
80%(43/54)
Active Trials
21(24%)
Results Posted
16%(7 trials)
Terminated
11(13%)

Phase Distribution

Ph not_applicable
22
25%
Ph phase_1
2
2%
Ph phase_2
6
7%
Ph phase_3
3
3%

Phase Distribution

2

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution33 total trials
Phase 1Safety & dosage
2(6.1%)
Phase 2Efficacy & side effects
6(18.2%)
Phase 3Large-scale testing
3(9.1%)
N/ANon-phased studies
22(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

69.4%

43 of 62 finished

Non-Completion Rate

30.6%

19 ended early

Currently Active

21

trials recruiting

Total Trials

88

all time

Status Distribution
Active(21)
Completed(43)
Terminated(19)
Other(5)

Detailed Status

Completed43
Active, not recruiting11
Terminated11
Recruiting10
Withdrawn8
unknown5

Development Timeline

Analytics

Development Status

Total Trials
88
Active
21
Success Rate
79.6%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (6.1%)
Phase 26 (18.2%)
Phase 33 (9.1%)
N/A22 (66.7%)

Trials by Status

unknown56%
active_not_recruiting1113%
recruiting1011%
withdrawn89%
completed4349%
terminated1113%

Recent Activity

Clinical Trials (88)

Showing 20 of 88 trialsScroll for more
NCT02402244

Project: Every Child for Younger Patients With Cancer

Recruiting
NCT02194738Not Applicable

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Active Not Recruiting
NCT02465060Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Active Not Recruiting
NCT02688517

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

Recruiting
NCT02664883

Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer

Active Not Recruiting
NCT02474160

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

Recruiting
NCT00542373Not Applicable

Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer

Active Not Recruiting
NCT00867464

Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls

Active Not Recruiting
NCT01050504

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

Recruiting
NCT03057626

Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

Active Not Recruiting
NCT02215928

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

Recruiting
NCT02352883Not Applicable

MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

Active Not Recruiting
NCT00625066

Biological, Genetic, and Lifestyle Risk Factors for Developing Colorectal Adenomas or Polyps in Participants Undergoing Colonoscopy

Completed
NCT02250352

Core Biopsies for Establishing a Breast Tumor Tissue Repository

Recruiting
NCT00904241

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Active Not Recruiting
NCT04526587

Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors

Recruiting
NCT02280161

Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer

Recruiting
NCT01137643

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Recruiting
NCT02003209Phase 3

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Completed
NCT02816879Not Applicable

Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men

Active Not Recruiting

Drug Details

Intervention Type
OTHER
Total Trials
88